Bioprosthetic Total Artificial Heart Induces a Profile of Acquired Hemocompatibility With Membranes Recellularization.

David M.Smadja PharmD, PhD, BrunoSaubaméa PhD, SophieSusen MD, PhD, MichelKindo MD, PhD, PatrickBruneval MD, PhD, EricVan Belle MD, PhD, PietJansenMD, Jean-ChristianRoussel MD, PhD , Christian Latrémouille MD, AlainCarpentier MD, PhD.

The Carmat total artificial heart (C-TAH) (Vélizy-Villacoublay, France) is an implantable electro-hydraulically actuated biventricular pump that has been developed to minimize mechanical assist device-related morbidities (1). Its blood-contacting surfaces consist of expanded polytetrafluoroethylene and bovine pericardial tissue processed in glutaraldehyde as used in cardiac bioprosthetic valves. In the 3 first implanted patients, we investigated biological parameters of hemocompatibility (hemolysis and appearance of acquired von Willebrand syndrome) and histological characteristics of explanted devices. The 3 patients were 76, 68, and 74 years of age with severe end-stage biventricular heart failure. Patient 1 made a rapid recovery after implantation but remained in intensive care because of respiratory and renal dysfunction. Patient 2 was successfully rehabilitated and could be discharged from the hospital after 5 months. Both patients experienced a device failure and died after 74 and 270 days, respectively. Patient 3 was discharged home at 5 months. Repeated rehospitalizations for asthenia, cachexia, and renal insufficiency led to the patient’s death at 254 days.

Bioprosthetic Total Artificial Heart Induces a Profile of Acquired Hemocompatibility With Membranes Recellularization.

Donnez votre avis